An analysis of the IFNβ therapy efficacy in RRMS patients revealed that during their reproductive years, females showed a more robust immune response, a higher absolute number of CD4+ lymphocytes, and a higher production of Th1-derived cytokines than males (e.g., interferon gamma, IFNγ, and IL-12), that might explain the different response to the same drug [39]. The gene discussed is IFNG; the disease is relapsing-remitting multiple sclerosis.